Actinomycetoma and advances in its treatment

Welsh, Oliverio; Vera-Cabrera, Lucio; Welsh, Esperanza; Salinas, Mario Cesar

doi:10.1016/j.clindermatol.2011.06.027

Cited by 75 publications

(77 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, actinomycetoma is treated with antibacterials. The most common drug treatment for uncomplicated cases is trimethoprim-sulfamethoxazole (TMP-SMX) given for several months until cure is achieved [66], [67]. A study in the 1970s by Mahgoub evaluated several antimicrobial combinations in 144 patients with actinomycetoma.…”

Section: Treatmentmentioning

confidence: 99%

The Mycetoma Knowledge Gap: Identification of Research Priorities

et al. 2014

Self Cite

View full text Add to dashboard Cite

Mycetoma is a tropical disease which is caused by a taxonomically diverse range of actinomycetes (actinomycetoma) and fungi (eumycetoma). The disease was only recently listed by the World Health Organization (WHO) as a neglected tropical disease (NTD). This recognition is the direct result of a meeting held in Geneva on February 1, 2013, in which experts on the disease from around the world met to identify the key research priorities needed to combat mycetoma. The areas that need to be addressed are highlighted here. The initial priority is to establish the incidence and prevalence of the disease in regions where mycetoma is endemic, prior to determining the primary reservoirs of the predominant causal agents and their mode of transmission to susceptible individuals in order to establish novel interventions that will reduce the impact of the disease on individuals, families, and communities. Critically, economical, reliable, and effective methods are required to achieve early diagnosis of infections and consequential improved therapeutic outcomes. Molecular techniques and serological assays were considered the most promising in the development of novel diagnostic tools to be used in endemic settings. Improved strategies for treating eumycetoma and actinomycetoma are also considered.

show abstract

Section: Treatmentmentioning

confidence: 99%

The Mycetoma Knowledge Gap: Identification of Research Priorities

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…They are a public healthcare problem in this zone including Sudan and Sahel, the Middle East, the Indian sub-continent, Latin America [1,2,6]. Sporadic cases have been reported in North Africa and the Antilles [2,6,7]. The occurrence of mycetomas in temperate zones [8,9], in travellers [6,10,11] is rare but possible.…”

Section: Epidemiologymentioning

confidence: 96%

“…Thirteen species of actinomycetes and at least 30 species of fungi have been identified (but new causative species are regularly identified, especially by PCR) [2,6,7,12]. Sixty per cent of mycetomas are caused by actinomycetes.…”

Section: Pathogenic Agentsmentioning

confidence: 98%

Management of mycetomas in France

Mattioni

Develoux

Brun

et al. 2013

Médecine et Maladies Infectieuses

View full text Add to dashboard Cite

“…The use of amphotericin B has been largely abandoned because of its toxicity and lower efficacy. The most commonly described regimen to treat actinomycetoma is streptomycin plus either trimethoprim-sulfamethoxazole or dapsone (15,16). The duration of therapy depends on the patient’s response and ranges from several months to two years.…”

Section: Diagnosismentioning

confidence: 99%